In R-MS patients treated with ocrelizumab, NEDA-S was 47.9% and 47.5% compared with 29.2% and 25.1% of IFN-treated patients for the two OPERA trials (p<0.001), but these findings were considered to be nonconfirmatory as a result of failure of the hierarchical analysis (59). This evidence concerns the gene IFNA1 and myeloid sarcoma.